KDR and osteosarcoma: Moreover, we found that co-targeting VEGFR2 and JMJD3 by encapsulating GSH-scavenging nanoparticles (NPs) could effectively eradicate chemotherapy-resistant osteosarcoma stem-like/progenitor cell-derived tumors (Scheme 1).